First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
- 1 June 2008
- journal article
- research article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 192 (6), 406-411
- https://doi.org/10.1192/bjp.bp.107.037184
Abstract
Background: The increased prevalence of diabetes in schizophrenia is partly attributed to antipsychotic treatment, in particular second-generation antipsychotics, but the evidence has not been systematically reviewed.Aims: Systematic review and meta-analysis comparing diabetes risk for different antipsychotics in people with schizophrenia.Method: We searched MEDLINE, PsycINFO, EMBASE, International Pharmaceutical Abstracts, CINAHL and Web of Knowledge until September 2006. Studies were eligible for inclusion if the design was cross-sectional, case-control, cohort or a controlled trial in individuals with schizophrenia or related psychotic disorders, where second-generation antipsychotics (defined as clozapine, olanzapine, risperidone and quetiapine) were compared with first-generation antipsychotics and diabetes was an outcome. Data were pooled using random effects inverse variance weighted meta-analysis.Results: Of the studies that met the inclusion criteria (n=14), 11 had sufficient data to include in the meta-analysis. Four of these were retrospective cohort studies. The relative risk of diabetes in patients with schizophrenia prescribed one of the second-generation v. first-generation antipsychotics was 1.32 (95% CI 1.15-1.51). There were insufficient data to include aripiprazole, ziprasidone and amisulpride in this analysis.Conclusions: There is tentative evidence that the second-generation antipsychotics included in this study are associated with a small increased risk for diabetes compared with firstgeneration antipsychotics in people with schizophrenia. Methodological limitations were found in most studies, leading to heterogeneity and difficulty interpreting data. Regardless of type of antipsychotic, screening for diabetes in all people with schizophrenia should be routine.Keywords
This publication has 36 references indexed in Scilit:
- Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with SchizophreniaAmerican Journal of Epidemiology, 2006
- Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatmentEuropean Neuropsychopharmacology, 2006
- Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case‐control study of California Medicaid claimsPharmacoepidemiology and Drug Safety, 2005
- Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric InpatientsPsychiatric Services, 2004
- Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic MedicationsAmerican Journal of Psychiatry, 2004
- Schizophrenia, the metabolic syndrome and diabetesDiabetic Medicine, 2004
- Antipsychotic-Induced Type 2 Diabetes: Evidence From a Large Health Plan DatabaseJournal of Clinical Psychopharmacology, 2003
- The Risk of Diabetes During Olanzapine Use Compared With Risperidone UseThe Journal of Clinical Psychiatry, 2002
- Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 DiabetesThe Journal of Clinical Psychiatry, 2002
- Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug useJournal of Affective Disorders, 2002